Swedish registry study checks how tofacitinib works in ulcerative colitis patients
NCT ID NCT04338204
First seen Dec 08, 2025 · Last updated Jun 22, 2026 · Updated 28 times
Summary
This completed study in Sweden observed 102 people with ulcerative colitis who were prescribed tofacitinib as part of their normal care. Researchers used a national registry to track how well the drug controlled disease activity and whether patients stayed on treatment. The goal was to see how tofacitinib performs in real-world settings, not in a controlled experiment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Danderyds Hospital
Stockholm, 18257, Sweden
-
Daniel Molin
Kristianstad, 29185, Sweden
-
Ersta Sjukhus, Medicinkliniken, Fjällgatan 44
Stockholm, 11691, Sweden
-
Gävle Hospital
Gävle, 80324, Sweden
-
Karolinska Universitetssjukhuset i Solna, Eugeniavägen 3, B4-09,
Stockholm, 17176, Sweden
-
Mag-Tarmmedicinska kliniken, Universitetssjukhuset i Linköping
Linköping, 58185, Sweden
-
Medicinkliniken, Länssjukhuset Ryhov, Sjukhusgatan
Jönköping, 55185, Sweden
-
Medicinkliniken, Södra Älvsborgs Sjukhus Borås, Brämhultsvägen 53
Borås, Sweden
-
Medicinkliniken, Umeås Universitetssjukhus
Umeå, 50985, Sweden
-
Medicinmottagning 4, Medicinska Kliniken, Universitetssjukhuset Örebro
Örebro, 70185, Sweden
-
Medicinmottagningen gastroenterologi, Västmanlands sjukhus
Västerås, 72189, Sweden
-
Region skåne, Skånes Universitetssjukhus
Malmö, 20501, Sweden
-
SU/Sahlgrenska, Gastroenterologi & Hepatologi
Gothenburg, Göteborg, Sweden
-
Shiprock Consulting AB,
Lidingö, Sweden
-
Specialmedicin, Akademiska Sjukhuset, Sjukhusvägen ing 40
Uppsala, 75185, Sweden
-
Stockholm Gastro Center
Stockholm, 11486, Sweden
-
Ulf Eriksson
Alingsås, SE-441 33, Sweden
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tofacitinib
What this could lead to
If successful, this study could show how well tofacitinib works in everyday care for ulcerative colitis, helping doctors make better treatment decisions.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection. It cannot prove cause and effect.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.